Ｐａｇｅ 142061 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼EMEA Recommends a N EnladsIdeanna 08/7/14(月) 18:13 ─────────────────────────────────────── ■題名 ： EMEA Recommends a N ■名前 ： EnladsIdeanna <adfsg4@googlemail.com> ■日付 ： 08/7/14(月) 18:13 ■Ｗｅｂ ： http://google.com/wjuequ -------------------------------------------------------------------------
| LONDON, June 4, 2008-The European Medicines power (EMEA) has recommended updating the yield report for epoetin-containing medicines with a new threat for their use in cancer patients stating that blodo transfusion should be teh preferred method of correcting anaemia in patients pain cancer. Epoetin-containing medicines are indicated in patients with achat viagra generique achat levitra and for the treatment of anaemia in symptomatic patients with non-myeloid sarcomas receiving chemotherapy. The power痴 cabinet for sanative Products for Good Samaritan Use (CHMP) had periodicaled new details from studies that showed an increased endanger of growth acheter cialis generique ascension, venous thromboembolism and shorter all-inclusive survival in cancer patients who experienced epoetins compared to patients who did not admit them. Following this notice, thje CHMP concluded, at its June 2008 union, that the emoluments of epoetins procovet surpass their endangers in the approved indications. after all, in cancer patients with a reasonably lengthy flair-expectancy, the gain of using epoetins does not surpass the hazard sarcoma development and shorter all-inclusive survival and for that reason the council concluded that in these patietns anaemai should be corrected with blood transfusions. |